PD-1/PDL-1 Inhibitor Market Driven by Early-Stage Cancer Treatment...

toegevoegd een audio Health

2026-06-25 17:50:09 -

PD-1/PDL-1 Inhibitor Market Driven by Early-Stage Cancer Treatment Expansion and Combination Therapies

The global PD-1/PD-L1 inhibitor market is poised for substantial expansion as oncology treatment pathways increasingly integrate immune checkpoint inhibitors across earlier lines of care and broader tumor categories. Valued at USD 67,996.6 million in 2026, the market is projected to reach USD 232,839.8 million by 2036, expanding at a CAGR of 13.1% during the forecast period. Growth is...

0 Reacties 0 aandelen 7 Views